These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16488444)

  • 41. A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats.
    Shinoda M; Tilles AW; Kobayashi N; Wakabayashi G; Takayanagi A; Totsugawa T; Harada H; Obara H; Suganuma K; Berthiaume F; Shimazu M; Shimizu N; Tanaka N; Kitajima M; Tompkins RG; Toner M; Yarmush ML
    J Surg Res; 2007 Jan; 137(1):130-40. PubMed ID: 17081566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Matrix metalloproteinase-9 contributes to parenchymal hemorrhage and necrosis in the remnant liver after extended hepatectomy in mice.
    Ohashi N; Hori T; Chen F; Jermanus S; Eckman CB; Nakao A; Uemoto S; Nguyen JH
    World J Gastroenterol; 2012 May; 18(19):2320-33. PubMed ID: 22654423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat.
    Knittel T; Mehde M; Grundmann A; Saile B; Scharf JG; Ramadori G
    Histochem Cell Biol; 2000 Jun; 113(6):443-53. PubMed ID: 10933221
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats.
    Tsubokawa T; Solaroglu I; Yatsushige H; Cahill J; Yata K; Zhang JH
    Stroke; 2006 Jul; 37(7):1888-94. PubMed ID: 16763180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
    Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Matrix metalloproteinase-9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy: A pilot study in mice.
    Hori T; Uemoto S; Walden LB; Chen F; Baine AM; Hata T; Kogure T; Nguyen JH
    Hepatol Res; 2014 Jun; 44(6):651-62. PubMed ID: 23672352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain.
    Rosenberg GA; Estrada EY; Dencoff JE
    Stroke; 1998 Oct; 29(10):2189-95. PubMed ID: 9756602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
    Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
    Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in rat hippocampus.
    Pérez-Hernández M; Fernández-Valle ME; Rubio-Araiz A; Vidal R; Gutiérrez-López MD; O'Shea E; Colado MI
    Neuropharmacology; 2017 May; 118():157-166. PubMed ID: 28322979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
    Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
    Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
    Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
    Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition.
    Li H; Simon H; Bocan TM; Peterson JT
    Cardiovasc Res; 2000 May; 46(2):298-306. PubMed ID: 10773234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
    Peterson JT; Li H; Dillon L; Bryant JW
    Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of cold injury-induced brain edema with a nonspecific matrix metalloproteinase inhibitor MMI270 in rats.
    Kawai N; Kawanishi M; Nagao S
    Acta Neurochir Suppl; 2003; 86():291-5. PubMed ID: 14753455
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diffusion tensor imaging supports the cytotoxic origin of brain edema in a rat model of acute liver failure.
    Chavarria L; Oria M; Romero-Gimenez J; Alonso J; Lope-Piedrafita S; Cordoba J
    Gastroenterology; 2010 Apr; 138(4):1566-73. PubMed ID: 19843475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
    Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
    Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effects of shuxuening injection on the levels of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in acute exacerbated chronic obstructive pulmonary disease patients].
    Wang TJ; Xie ZH; Zhao ZZ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Feb; 32(2):191-4. PubMed ID: 22574591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in patients with tick-borne encephalitis.
    Palus M; Zampachová E; Elsterová J; Růžek D
    J Infect; 2014 Feb; 68(2):165-9. PubMed ID: 24091083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.